- Home
- IFRX vs RAND Comparison
IFRX vs RAND Comparison
Compare IFRX & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- RAND
- Stock Information
- Founded
- IFRX 2007
- RAND 1969
- Country
- IFRX Germany
- RAND United States
- Employees
- IFRX N/A
- RAND N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- IFRX Health Care
- RAND Finance
- Exchange
- IFRX Nasdaq
- RAND Nasdaq
- Market Cap
- IFRX 53.5M
- RAND 44.7M
- IPO Year
- IFRX 2017
- RAND N/A
- Fundamental
- Price
- IFRX $1.43
- RAND $14.37
- Analyst Decision
- IFRX Strong Buy
- RAND
- Analyst Count
- IFRX 5
- RAND 0
- Target Price
- IFRX $7.40
- RAND N/A
- AVG Volume (30 Days)
- IFRX 492.5K
- RAND 4.0K
- Earning Date
- IFRX 11-07-2025
- RAND 11-05-2025
- Dividend Yield
- IFRX N/A
- RAND 11.24%
- EPS Growth
- IFRX N/A
- RAND N/A
- EPS
- IFRX N/A
- RAND N/A
- Revenue
- IFRX $191,224.00
- RAND $7,966,118.00
- Revenue This Year
- IFRX N/A
- RAND N/A
- Revenue Next Year
- IFRX $1,216.24
- RAND N/A
- P/E Ratio
- IFRX N/A
- RAND N/A
- Revenue Growth
- IFRX 54.36
- RAND 1.16
- 52 Week Low
- IFRX $0.71
- RAND $13.82
- 52 Week High
- IFRX $2.82
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- IFRX 55.06
- RAND 41.83
- Support Level
- IFRX $1.29
- RAND $14.27
- Resistance Level
- IFRX $1.44
- RAND $15.22
- Average True Range (ATR)
- IFRX 0.14
- RAND 0.45
- MACD
- IFRX -0.00
- RAND 0.03
- Stochastic Oscillator
- IFRX 48.84
- RAND 10.21
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.